KRAS and non-small cell lung carcinoma: So far, the FDA has only approved the NGS-based Guardant360® liquid biopsy CDx for tumor mutation profiling to identify KRAS p.G12C mutated patients with locally advanced or metastatic NSCLC, who may benefit from sotorasib.